Risk factors for precancerous lesions of the cervix in a population of Georgian women

Similar documents
Human Papillomavirus

Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE

Objectives. Background. Background. Background. Background 9/26/16. Update on Cervical and HPV Screening Guidelines: To pap or not to pap?

Done by khozama jehad. Neoplasia of the cervix

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System

The Pap Smear Test. The Lebanese Society of Obstetrics and Gynecology. Women s health promotion series

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Prevention, Diagnosis and Treatment of Gynecologic Cancers

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Cervical Cancer Screening. David Quinlan December 2013

Proposed new national cervical screening program. Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns

Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida

Focus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection

What is cervical cancer?

What is a Pap smear?

WHAT IS CERVICAL CANCER? Presented by Dr. Sylvia Deganus

CERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.

HPV AND CERVICAL CANCER

HPV the silent killer, Prevention and diagnosis

Screening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck

HPV infections and potential outcomes

Pap Test. F r e q u e n t l y A s k e d Q u e s t i o n s

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS

I have no financial interests in any product I will discuss today.

FREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION

TISSUE TUMOR MARKER EXPRESSION IN

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

HPV/Cervical Cancer Resource Guide for patients and providers

Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???

Prevent You can prevent cancer of the cervix


HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

Lauren O Sullivan, D.O. February 19, 2015

News. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM

Gynecologic Oncology Overview Staging updates and Soap Box Issues

Protect yourself: Get screened for breast cancer

Shrestha P CORRESPONDENCE

Update on Cervical Cancer Screening. Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014

Update on Cervical Cancer Screening

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today.

Largest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

CERVICAL CANCER FACTSHEET. What is cervical cancer?

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

Cervical Cancer Prevention Month. January 2011 Morehouse College

Promoting Cervical Screening Information for Health Professionals. Cervical Cancer

Cervical Cancer Screening Guidelines Update

CEVIRA FINAL RESULTS OF PHASE 2B CLINICAL TRIAL. April 11, 2013

I have no financial interests in any product I will discuss today.

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

9/18/2008. Cervical Cancer Prevention for Adolescent Populations Garcia. Faculty disclosure. Objectives. HPV Positivity by Age (UK)

Human Papillomavirus (HPV) and Cervical Cancer Prevention

Cervical Cancer Screening

Continuity of care heuristic model for sequential HPV testing over 3 tests with limited or extended genotyping

Medicare Adds New Screening Services for Human Papillomavirus (HPV) and Human Immunodeficiency Virus (HIV) March 2016

Your Colposcopy Visit

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64

HPV testing For women with high-grade abnormal Pap tests. p 1

The new Cervical Screening Test for Australian women: Louise Farrell

How do we compare? IP724/BMTRY Introduction to Global and Public Health. Feb 21, 2012 Basic Science Rm Sharon Bond, PhD, CNM

Hosp Lab Management (HLM) Service. HLM Tie-ups Cervical Screening & Diagnostics Tie-up Business Process Flow

Understand Your Results

Cervical cancer control in developing countries

What You Should Know. Exploring the Link between HPV and Cancer.

The Future of Cervical Screening. Jenny Ross

Sexual Health reproduction in reference to treatment as/for prevention

X-Treme Primary Care: HPV and STIs. Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers

Comparing Liquid-Based Cytology Methods in the Detection of Cervical Cancer: Perspectives from Dr. Ming Guo

Cervical Cancer Curriculum Table of Contents

The Role of Epidemiologic Studies in Establishing HPV as a Cause of Cancer. April 2, 2008 Margaret M. Madeleine, PhD. Outline

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita

Making Sense of Your Pap and HPV Test Results

The impact of the HPV vaccine in Scotland.

SUPPLEMENTARY MATERIAL

Background HPV causes virtually all cervical cancers HPV-16, Integration of viral oncogenes E6 and E7 Relationship between HPV and cervical cancer wou

A Timely Decision A STORY ABOUT FACING BARRIERS IN ORDERTO PREVENT CERVICAL CANCER

Modeling optimal cervical cancer prevention strategies in Nigeria

Cervical Cancer Screening

National Cervical Screening Program MBS Item Descriptors

Cervical Screening. What Pacific women need to know

Paps & Pelvics: Where Do We Stand?

Adult Well Woman Screening Best Practices at CrossOver* Last updated

Human papillomavirus and vaccination for cervical cancer

Preventing cervical cancer Australia. The Renewed National Cervical Screening Program 2019 Common Questions and Cases

PATIENT INFORMATION. about CERVICAL CANCER

Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract

Index. Infect Dis Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.

The Pap Test. Last updated May, 2016

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

HPV HUMAN PAPILLOMA VIRUS

HPV facts about the virus, the vaccine and what this means for you. Answers to common questions asked by adolescents and young adults

Woo Dae Kang, Ho Sun Choi, Seok Mo Kim

No woman has to be diagnosed with cervical cancer. No woman has to die of cervical cancer.

PAP smear. (Papanicolaou Test)

No Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016

Overview CANCER. Cost Facts

WHAT PATIENTS BRING TO THE MEDICAL ENCOUNTER DEALING WITH THE WHOLE PATIENT FACULTY PACKET

Transcription:

Training Course in Sexual and Reproductive Health Research Geneva, 2 March 2009 Risk factors for precancerous lesions of the cervix in a population of Georgian women Maia Chiokadze, M.D. Medical Diagnostic Centre Microgen, Tbilisi, Georgia GFMER scholarship Tutor: Lale Say

Background: Cervical cancer remains one of the most important issues of oncogynecology worldwide, being not only a medical, but also a social problem. Cervical cancer is the most common cancer and leading cause (after breast cancer) of cancer-related death among middle-aged women in developing countries. Almost 260 000 death annually, from which approximately 80% occurs in developing countries. Some studies indicate that both incidence and mortality rate in developing countries are likely to be underestimated. Epidemiological pattern of cancer in developing countries may differ in many aspects: Cancer natural history Microbiologic environment Patient s immune system Drug availability

Prevalence of cervical cancer in developing countries In Georgia cervical cancer ranks as 2 nd most frequent cancer among women aged 15-44, but precise data about cervical precancerous lesions are not available.

The main cause of cervical precancerous and cancerous lesions is Persistent Human Papillomavirus (HPV) infection It can be detected in 70-90% of all cervical cancers. More than 120 known genotypes of HPV. 15 of them can cause cancer of cervix and other sites. The most oncogenic genotypes are HPV 16 and 18. These high-risk types are mostly associated with the persistence of infection. HPV is highly transmissible. It is the most common STI. Co-infection with multiple HPV occurs more frequently than expected.

Age-dependent prevalence of hrhpv Prevalence of HPV vary greatly around the world: between 2% and 44% From Br J cancer (2008); 98 Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. The dashed lines represent the lower and upper 99% confidence bands of the fitted curves.

Role of co-factors HPV positive women Virus clearence within 2 years HPV Negative hrhpv Risk co-factors CARCINOGENESIS Multistep Multifactorial process Current Epidemiologic Challenge: Identify potential risk cofactors (environmental, host) HSIL Cancer Potential risk co-factors: Women s age Parity Early sexual debut Smoking Multiple sexual partners Use of OC Other, non-hpv STIs

Objectives of the study To determine the real rate frequency of precancerous cervical lesions (CIN 1,2,3) in a population of women in Tbilisi (Georgia). To identify the risk co-factors and their significance to the development of high-grade CIN. To work out recommendations for preventing cervical precancerous lesions and to optimize FUP.

Materials and methods Study design: descriptive epidemiology Selection of participants: all women who attend our clinic for gynecological exam. Setting: Medical Diagnostic Centre Microgen with cooperation of Tbilisi Oncocentre. Data collection during the usual pelvic examination: Vaginal smear Culture of vaginal swab Pap smear Serology for anti-chlamydial IgM and IgG antibodies Colposcopy Outcome measures: CIN 1, 2, 3, confirmed by Pap Smear. Statistical Analysis: to assess the effect of potential risk co-factors, method of logistic regression will be used.

Expected benefits: Identify women at greatest and least risk for cervical precancerous lesions. Work out a risk management model (primary prevention). Rationalize clinical decisions. Better allocation of resources: increase safety for women at greatest risk and reduce unnecessary investigations and overtreatment for women at lowest risk. By educating women and their partners, creating awareness about the potential risk factors for cervical pre- and cancerous lesions.

Cervical cancer is completely preventable

Acknowledgements: GFMER WHO LECTURERS TUTOR: LALE SAY Thank you